Clay Siegall fights Cancer with Seattle Genetics

Clay Siegall is the co-founder of Seattle Genetics. He is also the companies President, Chief Executive Officer and Chairman of the Board. He earned a Ph.D in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He has written over 70 publications and has 15 patents. Siegel serves as the Board of Directors of two private biotechnology companies including Alder BioPharmaceuticals and Mirna Therapeutics. He has also secured $675 million in public and private financing.
Seattle Genetics was built around the concept of fighting cancer starting in 1998. This company is located in Bothell just north of Seattle. This company employs close to 1000 employees. The company vision is to improve the lives of people with cancer through innovative and empowered antibody-based therapies. Seattle Genetics has a robust product pipeline designed to address unmet medical needs. Siegall has lead the company in innovative research and has developed anti-drug conjugates (ACD) to treat cancer.
The company is the industry leader in anti- drug conjugates (ACD). With Clay Siegall‘s guidance, Seattle Genetics has multiple strategic licenses for its ACD technology. There are more than 20 ACD’s in clinical development using this technology. This type of treatment for cancer was designed to improve efficacy and reduce toxicity. The U.S. Food and Drug Administration approved ADCETRIS in 2011. This drug is making a difference in the lives of patients with Hodgkin lymphoma and systemic ALCL. ADCETRIS is now available in 47 countries. This includes the U.S., Canada, Japan, and the European Union.

Learn more:

Leave a Reply

Your email address will not be published. Required fields are marked *